Biotechnology

CanSinoBIO

CanSino Biologics' Adolescent and Adult Td5cp Vaccine NDA Gets Priority Review

CanSino's DTaP-Hib Vaccine Added to Priority Review

UBS Downgrades CanSino Biologics 2026 Target Price to HKD 52.4

CanSino Biologics Q1 2026 Revenue Growth and Net Loss

CanSinoBIO released FY2026 Q1 earnings on April 28 After-Market (BJT), actual revenue CNY 190.28 M, actual EPS CNY -0.16

CanSinoBIO FY2026 Q1 Earnings Release on April 28 After-Market BJT

CanSino Biologics Reports Profit in 2025, Enters New Stage of Value Realization

CanSino Biologics Reports 26.18% Profit Growth in 2025

CanSino's flagship product Manhesin expands age range

CanSino MCV4 and PCV13i Obtain GMP Certificate from Malaysia NPRA

CanSino Biologics Reports Profitable 2025 Earnings

CanSinoBIO released FY2025 Q4 earnings on February 26 Pre-Market (BJT), actual revenue CNY 375.34 M (forecast CNY 321.11 M), actual EPS CNY 0.046

CanSinoBIO released FY2025 earnings on February 26 Pre-Market (BJT), actual revenue CNY 1.068 B (forecast CNY 1.053 B), actual EPS CNY 0.11 (forecast CNY -0.04)

CanSinoBIO to Release FY2025 Earnings on March 5, 2026, Pre-Market BJT; Forecast Revenue CNY 1.053 B, EPS CNY -0.04

CanSino's Meningococcal Quadrivalent Conjugate Vaccine Approved for Older Age Group

Top Vaccine Companies Show Diverging Performance: ZhiFei Bio Reports Loss, KangXinNo and WoSen Bio Achieve Profit Turnaround

CanSino Biologics Expected to Turn Profit in 2025

CanSino Receives Approval for Clinical Trials of 24-Valent Pneumococcal Conjugate Vaccine

CanSino Biologics Starts I Phase Clinical Trial for DTcP-Hib-MCV4 Combination Vaccine

CanSino Biologics Starts Phase I Clinical Trials for Tetra-valent Vaccine

06185

688185

159102

159892

159849

159859

520880

159837

UBS has downgraded CANSINOBIO's target price to HKD52.4 while maintaining a Buy rating. The company's 1Q26 results were in line with expectations, reporting a revenue of RMB190 million, a 38.7% year-on-year increase, but a net loss of RMB40 million. UBS has also revised its EPS forecasts for 2026 to 2028 downward, reflecting a more cautious outlook for the company.

AASTOCKS News

CANSINOBIO

Huaan Hang Seng Biotech ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

China Merchants CSI Biotechnology Theme ETF

Tianhong CNI BIOMEDICINE ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

E Fund CSI Biotechnology Theme ETF

UBS Group AG

UBS Cuts CANSINOBIO  TP to HKD52.4; 1Q26 Results In Line

CanSino Biologics Inc. reported a 38.73% year-over-year revenue increase in Q1 2026, totaling RMB 190 million. The growth is attributed to strong sales of core products, including Menhycia(R) and iPneucia(R), and new revenue streams from international technology transfer. The company is expanding its vaccine portfolio and pursuing a global strategy, with recent approvals for new products and a focus on life-course immunization. CanSinoBIO aims to enhance its market presence and long-term value through innovation and global expansion.

Asian Corporate Newswire

CanSinoBIO Delivers Q1 Revenue Growth Amid Accelerating International Expansion

CANSINOBIO-0.260 (-0.805%) Short selling $1.07M; Ratio 2.709% 's 1Q26 operating revenue was approx. RMB190 million, up 38.73% YoY, as announced by CANSINOBIO. Net loss attributable to shareholders of the Company amounted to approx. RMB40.4243 million, compared with a loss of RMB11.5454 million in the corresponding period of last year. Basic loss per share stood at approx. RMB0.16.(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-04-28 16:25.) AASTOCKS Financial News

CANSINOBIO 1Q Net Loss Widens to RMB40.4243M

516930

588130

516820

512290

588250

CanSinoBIO achieved a total operating revenue of approximately CNY 1.068 billion in 2025, a year-on-year increase of 26.18%, with net profit successfully turning from loss to profit, reaching approximately CNY 27.8727 million. The improvement in performance is mainly attributed to the sales growth of its flagship product, Convidecia, which has received approval from the National Medical Products Administration to expand its applicable age to 6 years old, further expanding market space. However, CanSino still faces concerns about its product structure being too singular, with Convidecia accounting for as much as 90% of total revenue

BambooWorks

Minsheng Royal CSI Biotechnology Theme ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Yinhua CSI Innovative Drugs Industry ETF

E Fund CSI 300 Health Care ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Ping An CSI Medicine and Medical Device Innovation ETF

Guotai CSI Bio-medicine ETF

ICBCCS SSE STAR Biology and Medicine ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Penghua SSE STAR Biology and Medicine ETF

ChinaAMC CSI Biotechnology Theme ETF

Star product market expansion drives CanSinoBIO to turn a profit

159316

159615

159506

CanSino Biologics has reported a positive earnings report, defying a slowdown in the vaccine industry, with a 26% revenue increase to nearly 1.07 billion yuan in 2025. The company's profit turnaround was aided by state subsidies, but core earnings remain under pressure due to reliance on meningitis vaccines. The approval to expand the age limit for its meningitis vaccine, Menhycia, has boosted share prices. However, competition is increasing, and demographic challenges in China may impact future growth. CanSino is targeting international markets to mitigate domestic challenges.

benzinga_article

E Fund Hang Seng SCHK Innovative Drug ETF

China Southern Hang Seng Biotech ETF(QDII)

GF CSI HK Innovative Drugs Industry ETF(QDII)

Bosera Hang Seng SCHK Innovative Drug Select ETF

Bosera Hang Seng Health Care ETF(QDII)

Penghua CSI HK Connect Health Care Composite ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Meningitis Shot Delivers Dose Of Good Cheer For CanSino

CanSinoBIO (6185.HK) closed lower again on January 30, with occasional tentative buying during the day, but overall fluctuating around the 35 yuan level, lacking the momentum for a sustained rise. The pharmaceutical and innovative drug sectors have recently seen significant adjustments, affected by multiple regulatory pressures and capital withdrawals. CanSino itself has not had any major business updates recently, leading to a cautious and risk-averse market sentiment. Some institutions are attempting to buy at lower prices, but they struggle against overall short-selling pressure, resulting in low trading volumes. Only during short-term overselling do we see small buying orders entering, triggering panic selling with slight volume increases. Sector rebound and intraday capital movements are the only possibilities for future rebounds. From a technical perspective, MACD is weakening, and the K-line is inconsistent throughout the day, with insufficient market sentiment in the main board sector. If it falls below 34.88 yuan in the short term, it may further exacerbate the short-selling advantage. Operational advice: closely monitor intraday movements and sector rebound signals, and control positions until there is a clear return of capital. The overall strategy focuses on right-side following and defensive observation, with timely tracking of medical insurance and policy margins to seize short-term opportunities

Technical Forecast

Yinhua CSI Research Sector 100 ETF

Morning Trend | CANSINOBIO continues to decline, when will short-term buying return?

CanSinoBIO(688185.SH)

UBS Cuts CANSINOBIO TP to HKD52.4; 1Q26 Results In Line

CanSinoBIO Delivers Q1 Revenue Growth Amid Accelerating International Expansion

CANSINOBIO 1Q Net Loss Widens to RMB40.4243M

Star product market expansion drives CanSinoBIO to turn a profit

Meningitis Shot Delivers Dose Of Good Cheer For CanSino

Morning Trend | CANSINOBIO continues to decline, when will short-term buying return?